Looking at the universe of stocks we cover at Dividend Channel, on 4/29/13, First Community Corp. (FCCO - Get Report) will trade ex-dividend, for its quarterly dividend of $0.05, payable on 5/15/13. As a percentage of FCCO's recent stock price of $8.90, this dividend works out to approximately 0.56%, so look for shares of First Community Corp. to trade 0.56% lower — all else being equal — when FCCO shares open for trading on 4/29/13.Below is a dividend history chart for FCCO, showing historical dividends prior to the most recent $0.05 declared by First Community Corp. : In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from FCCO is likely to continue, and whether the current estimated yield of 2.25% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of FCCO shares, versus its 200 day moving average: Looking at the chart above, FCCO's low point in its 52 week range is $7.60 per share, with $9.25 as the 52 week high point — that compares with a last trade of $8.90. In Thursday trading, First Community Corp. shares are currently trading flat on the day.
More from Stocks
Stocks Higher as Investors Look to Jerome Powell for Hints on Fed Policy
Stocks are rising Thursday with investors looking to guidance from Fed Chairman Jerome Powell, who is scheduled to speak Friday.
Nordstrom's Mixed Earnings -- What Wall Street Is Saying
Nordstrom's discounting is concerning some analysts, while others question how long the retailer can cut costs.
Toro's Stock Jumps as Lawnmower Maker Beats Earnings Estimates
The CEO attributes a big jump in quarterly sales to the company's acquisition of Charles Machine Works, a maker of underground construction equipment.
Going Shopping? Jim Cramer Breaks Down Nordstrom's Quarter, Oil and Markets
Jim Cramer weighs in on Nordstrom's quarter, his latest thoughts on oil and the markets.
Retrophin Tanks After Neurological Treatment Fails Late-Stage Study
The treatment, fosmetpantotenate, fails to meet its primary endpoint when compared to a control group being treated with a placebo, the company says.